Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of propranolol, a non-selective beta-adrenergic receptor antagonist (beta blocker), and a proton-pump inhibitor (PPI), which is a class of drugs that suppress gastric acid secretion. Propranolol is primarily used to treat hypertension, arrhythmias, angina pectoris, migraine prophylaxis, and other cardiovascular conditions by blocking beta-adrenergic receptors in the heart and vasculature[6]. Proton-pump inhibitors such as omeprazole, pantoprazole, lansoprazole, rabeprazole, or esomeprazole are used to treat gastroesophageal reflux disease (GERD), peptic ulcers, and related acid-related disorders by irreversibly inhibiting the H+,K+-ATPase enzyme system on gastric parietal cells[4][8][9][10]. This combination may be prescribed when both cardiovascular management with propranolol and acid suppression with a PPI are required.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propranolol + proton-pump inhibitor.